Oncolytic Virus (OV) Therapy

As a global CRO offering ample laboratory capacity and extensive regulatory expertise, Creative Biolabs ensues our clients that fully compliant results will be delivered in the timelines promised. To support cancer cellular and gene therapy, we developed a comprehensive set of cutting-edge and innovative services for T Cell Receptor (TCR) T cell therapy, CAR-T cell therapy, CAR-macrophage cell therapy, CAR-NK cell therapy, as well as Oncolytic Virus (OV) therapy. Careful consideration of properties of OV and the clinical purpose to ensure the good start of your project.

As unique anticancer agents, oncolytic viruses (OVs) play the anticancer function via a series of modes of action, including tumor-restricted viral infection, replication, cell lysis, and spread. Now a panel of diverse viruses are genetically engineered for clinical investigation (see Fig.1).  Pleiotropic therapeutic activities of OVs include:

• Viral tumor cell lysis can trigger systemic antitumor immunity;
• Insertion of therapeutic genes can induce bystander killing via various approaches;
• Endothelial cells in tumor vessels are susceptible to OVs;
• Combination with vaccination or other immunotherapies, such as immune checkpoint inhibitors.

Fig.1 Diversity of oncolytic viruses and their modes of action. (Ungerechts, 2016)

Aided by our advanced OV therapy platform, Creative Biolabs offers customized, reliable, and superior integrated OV therapy development services for worldwide numerous clients. Our services include virus construction, engineering, in vitro and in vivo validation. Empowered by our well-established in-house OV engineering systems and GMP-compliant manufacture of OV, we aim to find the best OV candidate within the commitment timelines and required budget. With our unmatched knowledge of animal models, immunology, cancer expertise, Creative Biolabs is dedicated to assisting in developing the most promising OV candidate for our clients.

	Fully taking into considerations of the characteristics of various viruses; Well-established OV construction processes for a broad range of species; Specific design to fit different cancer types.
	Various engineering methods to enhance the antitumor immunity; Pathogenicity manipulation, immunogenicity manipulation, antibody-expressing OV, cytokine/chemokine-expressing OV, immune checkpoints inhibitor-expressing OV.
	A variety of in vitro assays for engineered OV to test the virus functional activities including but not limited to: plaque purification assay, identity assay, replication assay, tumor lytic assay, transgene expression assay, and transgene functional assay.
	Xenograft animal models; OV pharmacology testing including biodistribution/PK studies; OV toxicology evaluation including immunogenicity study and other studies.; OV efficacy testing.
	Increased capacity and scale to provide a variety of suspension and adherent platforms; GMP-compliant OV manufacture.

Highlights of Our OV Therapy Program

• Expertise: Across a broad range of disciplines;
• Collaboration: Clients focused collaboration with strategic approaches;
• Combination: Combination oncolytic virus therapy with other immunotherapies for cancer therapy;
• Streamlined development: End-to-end integrated solutions.

With the extensive experience and streamlined development for OV therapy, Creative Biolabs is fully competent and dedicated to our end-to-end OV therapy solutions for global clients. We can accommodate the specific requirements and properties of your product to propose the customized solutions to maximize the success of your projects. Please feel free to contact us to learn how we can be involved in your projects. Any individual modules or an integrated service package are welcomed.

Reference

1. Ungerechts, G.; et al. Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. Mol Ther Methods Clin Dev. 2016 Apr 6;3:16018.

For Research Use Only | Not For Clinical Use